ZIM
KNSA icon

Zacks Investment Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Zacks Investment Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-14,239
Closed -$363K – 536
2020
Q2 		$363K Buy
+14,239
New +$297K 0.01% 423

Other funds holding KNSA

HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Zacks Investment Management's KNSA Position: Q3 2020 in Review

Zacks Investment Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2020, closing a stake of 14,239 shares — an estimated $363K sold.

Zacks Investment Management first reported a position in KNSA in Q2 2020 and held it in 1 quarter. The position peaked at $363K in Q2 2020. 104 funds tracked by Wall St. Rank hold KNSA as of Q3 2020.

  • Zacks Investment Management reported no remaining Kiniksa Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Zacks Investment Management sold 14,239 Kiniksa Pharmaceuticals shares in Q3 2020, an estimated $363K.
  • Zacks Investment Management first reported a position in Kiniksa Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Zacks Investment Management's Kiniksa Pharmaceuticals position peaked at $363K in Q2 2020.
  • 104 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2020.

Based on Zacks Investment Management's 13F filing for Q3 2020, filed 16 Nov 2020.